Sequans Launches Iris: Next-Gen RF Integrated Transceivers for SDR Applications
The Iris product line comes from Sequans' strategic acquisition of ACP in early 2025. ACP, a recognized leader in RF semiconductor innovation, has shipped millions of RF transceivers powering advanced applications such as 5G small cells, drones, and V2X systems. This acquisition combines Sequans' leadership in IoT with ACP's deep RF expertise to deliver next-generation RF for SDR solutions.
Introducing the Iris SQN9506, Flagship of the Sequans Iris Family
The Iris SQN9506 is a wideband RF transceiver uniquely designed for high-performance, robust, multi-channel communication in a compact, power-efficient form factor. Key features include:
'With Iris, Sequans is redefining what's possible in Software Defined Radio technology - delivering unmatched performance, integration, and adaptability for the most demanding RF applications,' said Georges Karam, CEO and President of Sequans. 'The Iris line addresses previously unmet needs in mission-critical SDR applications. We are thrilled to integrate ACP's exceptional technology into this new product line.'
The launch of the Iris line marks a major milestone in Sequans' ongoing commitment to innovation and excellence in advanced semiconductors for critical IoT applications. The Iris SQN9506 is now available and shipping to early customers.
For more information, visit: www.sequans.com/iris
About Sequans
Sequans Communications S.A. (NYSE: SQNS) is a fabless semiconductor company with a Bitcoin treasury. We view Bitcoin as a long-term store of value and intend to strategically accumulate it as our primary treasury reserve asset. Our approach involves acquiring and holding Bitcoin using net proceeds from equity and debt issuances - executed from time to time based on market conditions - as well as cash generated from operations and intellectual property monetization.
Sequans is a leading semiconductor company specializing in wireless 4G/5G cellular technology for the Internet of Things (IoT). Our engineers design and develop innovative, secure, and scalable technologies that power the next generation of AI-connected applications - including secured payment, smart mobility and logistics, smart cities, industrial, e-health, and smart homes. We offer a comprehensive portfolio of solutions, including integrated circuits (IC) of baseband processors and radio frequency (RF) transceivers, modules, software, and protocol stacks. Our LTE-M/NB-IoT, 4G LTE Cat 1bis, and 5G NR RedCap/eRedCap platforms are purpose-built for IoT, delivering breakthroughs in wireless connectivity, power efficiency, security, and performance. We also provide advanced design services and technology licensing.
We believe our combination of a strategic Bitcoin reserve and deep focus on semiconductor innovation positions Sequans for long-term value creation.
Founded in 2003, Sequans is headquartered in France and operates globally, with offices in the United States, United Kingdom, Switzerland, Israel, Singapore, Finland, Taiwan, and China.
Visit Sequans at sequans.com and follow us on LinkedIn and X
Contacts
Sequans investor relations:
David Hanover/Gerrick Johnson, KCSA Strategic Communications (USA), +1 212.682.6300, [email protected]
Sequans media relations:
Linda Bouvet (France), +33 170721600 [email protected]
Forward-Looking Statements
This press release contains certain statements that are, or may be deemed to be, forward-looking statements with respect to the financial condition, results of operations and business of Sequans, including, but not limited to, with respect to the use of proceeds from the Offering and the Company's bitcoin treasury strategy and the exercise of the common warrants for cash prior to their expiration. These forward-looking statements include, but are not limited to, statements that are not historical fact. These forward-looking statements can be identified by the fact that they do not relate to historical or current facts. Forward-looking statements also often use words such as 'anticipate,' 'committed to', 'target,' 'continue,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'goal,' 'believe,' 'hope,' 'aims,' 'continue,' 'could,' 'project,' 'should,' 'will' or other words of similar meaning. These statements are based on assumptions and assessments made by Sequans in light of its experience and perception of historical trends, current conditions, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve risk and uncertainty, because they relate to events and depend on circumstances that will occur in the future and the factors described in the context of such forward-looking statements in this announcement could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to be correct, and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this announcement.
Forward-looking statements are not guarantees of future performance. Such forward-looking statements involve known and unknown risks and uncertainties that could significantly affect expected results and are based on certain key assumptions. Such risks and uncertainties include, but are not limited to, potential adverse reactions or changes to business relationships resulting from the completion of the Qualcomm transaction or the Offering. Many factors could cause actual results to differ materially from those projected or implied in any forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are changes in the global, political, economic, business and competitive environments, market and regulatory forces, including tariffs and trade wars. If any one or more of these risks or uncertainties materialize or if any one or more of the assumptions prove incorrect, actual results may differ materially from those expected, estimated or projected. Such forward-looking statements should therefore be construed in the light of such factors. A more complete description of these and other material risks can be found in Sequans' filings with the SEC, including its annual report on Form 20-F for the year ended December 31, 2024, subsequent filings on Form 6-K and other documents that may be filed from time to time with the SEC. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this announcement. Sequans undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259760
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Why Arista Networks Stock Is Skyrocketing Wednesday
Arista Networks Inc. (NYSE:ANET) reported better-than-expected second-quarter financial results after markets closed on Tuesday. Revenues increased 30.4% year over year $2.21 billion, versus estimates of $2.11 billion and the management guidance of $2.1 billion. Adjusted EPS jumped to 73 cents from 53 cents a year ago, versus estimates of 65 cents. Gross margin was 65.2% in the second CFO, Chantelle Breithaupt, said, 'Non-GAAP operating income crossed $1 billion for the first time at Arista...' View more earnings on ANET Arista Networks expects third-quarter sales of $2.25 billion versus the consensus of $2.093 billion. Analysts' Reaction Following the impressive earnings report and upbeat guidance, several prominent financial institutions reiterated their positive stance on Arista Networks. Morgan Stanley maintained an Overweight rating, raising its price forecast from $120 to $125. Piper Sandler, while holding a Neutral rating, significantly increased its price forecast from $89 to $143. UBS and Goldman Sachs both maintained Buy ratings, lifting their price forecasts from $115 to $155. Keybanc upheld its Overweight rating, adjusting its price forecast from $115 to $145, while Evercore ISI Group maintained an Outperform rating, raising its forecast from $120 to $150. Needham also maintained a Buy rating, increasing its price forecast from $130 to $155. Price Action: ANET stock is trading higher by 18.1% to $139.50 at last check Wednesday. Read Next:Photo via Shutterstock Latest Ratings for ANET Date Firm Action From To Mar 2022 Wells Fargo Upgrades Equal-Weight Overweight Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Wells Fargo Maintains Equal-Weight View More Analyst Ratings for ANET View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? ARISTA NETWORKS (ANET): Free Stock Analysis Report This article Why Arista Networks Stock Is Skyrocketing Wednesday originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
OysterLink Poll: 1 in 4 Hospitality Workers Say Their Company Has No Job Openings in 2025
Los Angeles, California--(Newsfile Corp. - August 6, 2025) - A new poll from OysterLink finds that 26% of hospitality professionals say their company has no new jobs planned for 2025, raising questions about internal communication and hiring urgency within a sector still facing labor instability. Image 1To view an enhanced version of this graphic, please visit: The poll, which asked "Is your company currently hiring?", gathered more than a hundred responses from professionals in the restaurant and hospitality industry. Results showed: 26% – No new jobs planned 52% – I'm not currently with a company myself 13% – Hiring 1–10 new employees 9% – Hiring 10+ new employees The findings come as the latest data from the U.S. Bureau of Labor Statistics (BLS) shows a major decline in job openings in the sector. In June 2025, the number of openings in Accommodation and Food Services fell by 308,000, dropping from 1.06 million in May to 754,000—a sharp monthly decline that may reflect cooling demand or cautious hiring behavior. About OysterLink OysterLink is a leading job platform dedicated to the hospitality industry. We connect restaurants, hotels, and hospitality employers with skilled candidates across the U.S. With job listings, including server jobs in New York City or private chef jobs in Los Angeles, industry insights, and career resources, OysterLink helps professionals build rewarding careers in hospitality. Media ContactPR Representativeana@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?
Eli Lilly & Co. (NYSE:LLY) reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately $14.7 billion, up about 30% YoY, and adjusted EPS of $5.60, rising roughly 4% YoY. That follows Q1's adjusted EPS of $3.34 on revenue of $12.73 billion, which beat estimates by a modest margin. Shares have declined slightly year-to-date, underperforming some peers despite strong momentum from obesity and diabetes drug sales. Novo Nordisk's (NYSE:NVO) recent profit warning and concerns around compounded drug competition have put extra scrutiny on Lilly's pricing power and volume growth. Investors will focus on the sustainability of strong demand for Mounjaro and Zepbound. After a strong Q1, which saw sales of the two drugs pick up, the market will be looking for confirmation that this momentum has continued into Q2. Investors will also watch for updates on manufacturing capacity and any commentary on how the company is managing its supply chain to meet this demand. Beyond the leading drugs, attention will be on the performance of other key growth drivers like the cancer drug Verzenio. Updates on the company's broader pipeline, particularly its oral GLP-1 candidate orforglipron, will be important for assessing long-term growth prospects. Management's updated guidance, now projects FY2025 adjusted EPS in the $20.78 to $22.28 range, down from prior forecasts due to a one-time cost associated with the Scorpion Therapeutics acquisition. Investors will listen for commentary on whether full-year revenue and EPS targets still reflect operational momentum. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data